[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640561":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":32,"locations":18,"responsibleParty":43,"collaborators":18,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":18,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":18,"overallStatus":65,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":18},{"fullName":5,"class":6},"Ceric Sàrl","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Renal denervation","EXPERIMENTAL","Renal denervation (patient continue hypertension medication if applicable)",[13],"Device: Renal denervation",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Standard of care (patient continue hypertension medication if applicable)",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"DEVICE","Catheter-based renal denervation performed during a standard renal artery catheterization procedure using a dedicated renal denervation system, according to the study protocol. The procedure is performed in addition to ongoing antihypertensive medical therapy, which is continued throughout the study as clinically indicated.",[9],[25,29],{"name":26,"affiliation":27,"role":28},"Felix Mahfoud, Prof.","Departement Biomedizin DBM Hebelstrasse","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":31,"role":28},"Roxana Mehran, Prof.","Icahn School of Medicine at Mount Sinai",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Estelle Darrau, Ph.D","CONTACT","0675657408","+33","edarrau@cerc-europe.org",{"name":40,"role":35,"phone":41,"phoneExt":37,"email":42},"laure Morsiani, Ph.D","0176739236","lmorsiani@cerc-europe.org",{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100640561","expand-management-of-blood-pressure-with-renal-denervation-in-patients-undergoing-staged-pci-for-advanced-coronary-artery-disease-100640561",false,"NCT07602790","Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE","Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery Disease","EMBRACE","Inclusion Criteria:\n\n* Subject with multi-vessel disease\n* Having successful index PCI and planned staged procedure within 1-6 weeks to complete revascularization\n* Subjects ≥21 years of age\n* Office systolic blood pressure at index procedure and\u002For staged procedure (systolic blood pressure \\>140 mmHg) while taking 2 or more antihypertensive drugs\n* Subject agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study prior to staged procedure\n\nExclusion Criteria:\n\n* \\- Contraindication for RDN outlined by IFU\n* Acute MI at time of the staged PCI procedure (AMI at time of the index PCI is allowed)\n* Subject has undergone prior renal denervation.\n* Subject has renal artery anatomy that is ineligible for RDN treatment per Symplicity Spyral™ IFU\n* Known secondary cause (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, or other identifiable etiologies).\n* Severe renal failure (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²)\n* Known LVEF \\\u003C30%\n* Known history of polycystic kidney disease, unilateral kidney, or undergone renal transplant\n* Mechanical circulatory support during PCI\n* Subject is under judicial protection, tutorship or curatorship\n* Failure of index procedure\n* Acute MI, severe renal failure, need for mechanical circulatory support, or legal incapacity between the index and staged procedures resulting in loss of eligibility.","ALL","21 Years",{"count":56,"type":57},1000,"ESTIMATED","INTERVENTIONAL",[60],"NA","EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for multivessel coronary artery disease.",[63,64],"Multivessel Coronary Artery Disease","Hypertension Resistant to Conventional Therapy","NOT_YET_RECRUITING","2026-05-18",{"date":68,"type":69},"2026-05-22","ACTUAL",{"date":71,"type":57},"2026-11",{"date":73,"type":57},"2033-11",{"name":5,"class":6}]